Related transplantation with HLA-1Ag mismatch in the GVH direction and HLA-8/8 allele-matched unrelated transplantation

A nationwide retrospective study

Junya Kanda, Hiroh Saji, Takahiro Fukuda, Takeshi Kobayashi, Koichi Miyamura, Tetsuya Eto, Mineo Kurokawa, Heiwa Kanamori, Takehiko Mori, Michihiro Hidaka, Koji Iwato, Takashi Yoshida, Hisashi Sakamaki, Junji Tanaka, Keisei Kawa, Yasuo Morishima, Ritsuro Suzuki, Yoshiko Atsuta, Yoshinobu Kanda

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

To clarify which is preferable, a related donor with an HLA-1 Ag mismatch at the HLA-A, HLA-B, or HLA-DR loci in the graft-versus-host (GVH) direction (RD/1AG-MM-GVH) or an HLA 8/8-allele (HLA-A, HLA-B, HLA-C, and HLA-DRB1)-matched unrelated donor (8/8-MUD), we evaluated 779 patients with acute leukemia, chronic myelogenous leukemia, or myelodysplastic syndrome who received a T cell-replete graft from an RD/1AG-MMGVH or 8/8-MUD. The use of an RD/1AGMM-GVH donor was significantly associated with a higher overall mortality rate than the use of an 8/8-MUD in a multivariate analysis (hazard ratio, 1.49; P < .001), and this impact was statistically significant only in patients with standard-risk diseases (P = .001). Among patients with standard-risk diseases who received transplantation from an RD/1AG-MM-GVH donor, the presence of an HLA-B Ag mismatch was significantly associated with a lower overall survival rate than an HLA-DR Ag mismatch because of an increased risk of treatment-related mortality. The HLA-C Ag mismatch or multiple allelic mismatches were frequently observed in the HLA-B Ag-mismatched group, and were possibly associated with the poor outcome. In conclusion, an 8/8-MUD should be prioritized over an RD/1AG-MM-GVH donor during donor selection. In particular, an HLA-B Ag mismatch in the GVH direction has an adverse effect on overall survival and treatment-related mortality in patients with standard-risk diseases.

Original languageEnglish
Pages (from-to)2409-2416
Number of pages8
JournalBlood
Volume119
Issue number10
DOIs
Publication statusPublished - 2012 Mar 8

Fingerprint

Transplantation (surgical)
Grafts
HLA-B Antigens
Retrospective Studies
Transplantation
Alleles
Transplants
Tissue Donors
HLA-C Antigens
HLA-A Antigens
HLA-DR Antigens
Mortality
HLA-DRB1 Chains
Donor Selection
Unrelated Donors
T-cells
Myelodysplastic Syndromes
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Direction compound
Hazards

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Related transplantation with HLA-1Ag mismatch in the GVH direction and HLA-8/8 allele-matched unrelated transplantation : A nationwide retrospective study. / Kanda, Junya; Saji, Hiroh; Fukuda, Takahiro; Kobayashi, Takeshi; Miyamura, Koichi; Eto, Tetsuya; Kurokawa, Mineo; Kanamori, Heiwa; Mori, Takehiko; Hidaka, Michihiro; Iwato, Koji; Yoshida, Takashi; Sakamaki, Hisashi; Tanaka, Junji; Kawa, Keisei; Morishima, Yasuo; Suzuki, Ritsuro; Atsuta, Yoshiko; Kanda, Yoshinobu.

In: Blood, Vol. 119, No. 10, 08.03.2012, p. 2409-2416.

Research output: Contribution to journalArticle

Kanda, J, Saji, H, Fukuda, T, Kobayashi, T, Miyamura, K, Eto, T, Kurokawa, M, Kanamori, H, Mori, T, Hidaka, M, Iwato, K, Yoshida, T, Sakamaki, H, Tanaka, J, Kawa, K, Morishima, Y, Suzuki, R, Atsuta, Y & Kanda, Y 2012, 'Related transplantation with HLA-1Ag mismatch in the GVH direction and HLA-8/8 allele-matched unrelated transplantation: A nationwide retrospective study', Blood, vol. 119, no. 10, pp. 2409-2416. https://doi.org/10.1182/blood-2011-08-372573
Kanda, Junya ; Saji, Hiroh ; Fukuda, Takahiro ; Kobayashi, Takeshi ; Miyamura, Koichi ; Eto, Tetsuya ; Kurokawa, Mineo ; Kanamori, Heiwa ; Mori, Takehiko ; Hidaka, Michihiro ; Iwato, Koji ; Yoshida, Takashi ; Sakamaki, Hisashi ; Tanaka, Junji ; Kawa, Keisei ; Morishima, Yasuo ; Suzuki, Ritsuro ; Atsuta, Yoshiko ; Kanda, Yoshinobu. / Related transplantation with HLA-1Ag mismatch in the GVH direction and HLA-8/8 allele-matched unrelated transplantation : A nationwide retrospective study. In: Blood. 2012 ; Vol. 119, No. 10. pp. 2409-2416.
@article{348b48219e75465abe082bd31c1a4167,
title = "Related transplantation with HLA-1Ag mismatch in the GVH direction and HLA-8/8 allele-matched unrelated transplantation: A nationwide retrospective study",
abstract = "To clarify which is preferable, a related donor with an HLA-1 Ag mismatch at the HLA-A, HLA-B, or HLA-DR loci in the graft-versus-host (GVH) direction (RD/1AG-MM-GVH) or an HLA 8/8-allele (HLA-A, HLA-B, HLA-C, and HLA-DRB1)-matched unrelated donor (8/8-MUD), we evaluated 779 patients with acute leukemia, chronic myelogenous leukemia, or myelodysplastic syndrome who received a T cell-replete graft from an RD/1AG-MMGVH or 8/8-MUD. The use of an RD/1AGMM-GVH donor was significantly associated with a higher overall mortality rate than the use of an 8/8-MUD in a multivariate analysis (hazard ratio, 1.49; P < .001), and this impact was statistically significant only in patients with standard-risk diseases (P = .001). Among patients with standard-risk diseases who received transplantation from an RD/1AG-MM-GVH donor, the presence of an HLA-B Ag mismatch was significantly associated with a lower overall survival rate than an HLA-DR Ag mismatch because of an increased risk of treatment-related mortality. The HLA-C Ag mismatch or multiple allelic mismatches were frequently observed in the HLA-B Ag-mismatched group, and were possibly associated with the poor outcome. In conclusion, an 8/8-MUD should be prioritized over an RD/1AG-MM-GVH donor during donor selection. In particular, an HLA-B Ag mismatch in the GVH direction has an adverse effect on overall survival and treatment-related mortality in patients with standard-risk diseases.",
author = "Junya Kanda and Hiroh Saji and Takahiro Fukuda and Takeshi Kobayashi and Koichi Miyamura and Tetsuya Eto and Mineo Kurokawa and Heiwa Kanamori and Takehiko Mori and Michihiro Hidaka and Koji Iwato and Takashi Yoshida and Hisashi Sakamaki and Junji Tanaka and Keisei Kawa and Yasuo Morishima and Ritsuro Suzuki and Yoshiko Atsuta and Yoshinobu Kanda",
year = "2012",
month = "3",
day = "8",
doi = "10.1182/blood-2011-08-372573",
language = "English",
volume = "119",
pages = "2409--2416",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Related transplantation with HLA-1Ag mismatch in the GVH direction and HLA-8/8 allele-matched unrelated transplantation

T2 - A nationwide retrospective study

AU - Kanda, Junya

AU - Saji, Hiroh

AU - Fukuda, Takahiro

AU - Kobayashi, Takeshi

AU - Miyamura, Koichi

AU - Eto, Tetsuya

AU - Kurokawa, Mineo

AU - Kanamori, Heiwa

AU - Mori, Takehiko

AU - Hidaka, Michihiro

AU - Iwato, Koji

AU - Yoshida, Takashi

AU - Sakamaki, Hisashi

AU - Tanaka, Junji

AU - Kawa, Keisei

AU - Morishima, Yasuo

AU - Suzuki, Ritsuro

AU - Atsuta, Yoshiko

AU - Kanda, Yoshinobu

PY - 2012/3/8

Y1 - 2012/3/8

N2 - To clarify which is preferable, a related donor with an HLA-1 Ag mismatch at the HLA-A, HLA-B, or HLA-DR loci in the graft-versus-host (GVH) direction (RD/1AG-MM-GVH) or an HLA 8/8-allele (HLA-A, HLA-B, HLA-C, and HLA-DRB1)-matched unrelated donor (8/8-MUD), we evaluated 779 patients with acute leukemia, chronic myelogenous leukemia, or myelodysplastic syndrome who received a T cell-replete graft from an RD/1AG-MMGVH or 8/8-MUD. The use of an RD/1AGMM-GVH donor was significantly associated with a higher overall mortality rate than the use of an 8/8-MUD in a multivariate analysis (hazard ratio, 1.49; P < .001), and this impact was statistically significant only in patients with standard-risk diseases (P = .001). Among patients with standard-risk diseases who received transplantation from an RD/1AG-MM-GVH donor, the presence of an HLA-B Ag mismatch was significantly associated with a lower overall survival rate than an HLA-DR Ag mismatch because of an increased risk of treatment-related mortality. The HLA-C Ag mismatch or multiple allelic mismatches were frequently observed in the HLA-B Ag-mismatched group, and were possibly associated with the poor outcome. In conclusion, an 8/8-MUD should be prioritized over an RD/1AG-MM-GVH donor during donor selection. In particular, an HLA-B Ag mismatch in the GVH direction has an adverse effect on overall survival and treatment-related mortality in patients with standard-risk diseases.

AB - To clarify which is preferable, a related donor with an HLA-1 Ag mismatch at the HLA-A, HLA-B, or HLA-DR loci in the graft-versus-host (GVH) direction (RD/1AG-MM-GVH) or an HLA 8/8-allele (HLA-A, HLA-B, HLA-C, and HLA-DRB1)-matched unrelated donor (8/8-MUD), we evaluated 779 patients with acute leukemia, chronic myelogenous leukemia, or myelodysplastic syndrome who received a T cell-replete graft from an RD/1AG-MMGVH or 8/8-MUD. The use of an RD/1AGMM-GVH donor was significantly associated with a higher overall mortality rate than the use of an 8/8-MUD in a multivariate analysis (hazard ratio, 1.49; P < .001), and this impact was statistically significant only in patients with standard-risk diseases (P = .001). Among patients with standard-risk diseases who received transplantation from an RD/1AG-MM-GVH donor, the presence of an HLA-B Ag mismatch was significantly associated with a lower overall survival rate than an HLA-DR Ag mismatch because of an increased risk of treatment-related mortality. The HLA-C Ag mismatch or multiple allelic mismatches were frequently observed in the HLA-B Ag-mismatched group, and were possibly associated with the poor outcome. In conclusion, an 8/8-MUD should be prioritized over an RD/1AG-MM-GVH donor during donor selection. In particular, an HLA-B Ag mismatch in the GVH direction has an adverse effect on overall survival and treatment-related mortality in patients with standard-risk diseases.

UR - http://www.scopus.com/inward/record.url?scp=84863230103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863230103&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-08-372573

DO - 10.1182/blood-2011-08-372573

M3 - Article

VL - 119

SP - 2409

EP - 2416

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -